These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7493344)

  • 1. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
    Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
    Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment.
    Blend MJ; Hyun H; Kozloff M; Levi H; Mills GQ; Gasparini M; Buraggi G; Hughes L; Pinsky CM; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5764s-5770s. PubMed ID: 7493343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
    Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
    Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas.
    Baum RP; Niesen A; Hertel A; Adams S; Kojouharoff G; Goldenberg DM; Hör G
    Cancer; 1994 Feb; 73(3 Suppl):896-9. PubMed ID: 8306276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
    Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
    Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
    Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 67Ga scintigraphy in B-cell non-Hodgkin's lymphoma: correlation of 67Ga uptake with histology and transferrin receptor expression.
    Nejmeddine F; Raphael M; Martin A; Le Roux G; Moretti JL; Caillat-Vigneron N
    J Nucl Med; 1999 Jan; 40(1):40-5. PubMed ID: 9935054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
    Vose JM; Colcher D; Gobar L; Bierman PJ; Augustine S; Tempero M; Leichner P; Lynch JC; Goldenberg D; Armitage JO
    Leuk Lymphoma; 2000 Jun; 38(1-2):91-101. PubMed ID: 10811451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
    Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
    Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL).
    Lamonica D; Czuczman M; Nabi H; Klippenstein D; Grossman Z
    Cancer Biother Radiopharm; 2002 Dec; 17(6):689-97. PubMed ID: 12537673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
    Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
    Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
    Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
    Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas.
    Ziegels P; Nocaudie M; Huglo D; Deveaux M; Detourmignies L; Wattel E; Marchandise X
    Eur J Nucl Med; 1995 Feb; 22(2):126-31. PubMed ID: 7758499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma.
    Waxman AD; Eller D; Ashook G; Ramanna L; Brachman M; Heifetz L; McAndrews P; Bierman H; Taub R; Avedo M; Wall F
    J Nucl Med; 1996 Jan; 37(1):46-50. PubMed ID: 8544000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
    Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
    Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of radioimmunoscintigraphy of non-Hodgkin's lymphoma with radiolabelled LL2 monoclonal antibody, LymphoSCAN: preliminary results.
    Gasparini M; Bombardieri E; Tondini C; Maffioli L; Hughes L; Burraggi GL; Goldenberg DM
    Tumori; 1995; 81(3):173-8. PubMed ID: 7571023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
    Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
    J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoma imaging with a new technetium-99m labelled antibody, LL2.
    Murthy S; Sharkey RM; Goldenberg DM; Lee RE; Pinsky CM; Hansen HJ; Burger K; Swayne LC
    Eur J Nucl Med; 1992; 19(6):394-401. PubMed ID: 1618230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.